Aprotinin


Concise Prescribing Info
Indications/Uses
Prophylaxis of perioperative blood loss in patients undergoing coronary artery bypass graft
Dosage/Direction for Use
Adult : IV Administer 10,000 KIU test dose 10 minutes before surgery. Loading dose: 1,000,000-2,000,000 KIU via slow IV inj or infusion over 20-30 minutes after induction of anaesthesia, followed by 250,000-500,000 KIU/hour via continuous infusion until end of the operation. An additional dose of 1,000,000-2,000,000 KIU is added to the pump prime of the heart-lung machine. Max: 7,000,000 KIU. Max rate: 5-10 mL/min.
Dosage Details
Intravenous
Prophylaxis of perioperative blood loss in patients undergoing coronary artery bypass graft
Adult: Administer 10,000 KIU test dose 10 minutes before surgery. Loading dose: 1,000,000-2,000,000 KIU via slow IV inj or infusion over 20-30 minutes after induction of anaesthesia, followed by 250,000-500,000 KIU/hour via continuous infusion until end of the operation. An additional dose of 1,000,000-2,000,000 KIU is added to the pump prime of the heart-lung machine. Max: 7,000,000 KIU. Max rate: 5-10 mL/min.
Incompatibility
Incompatible with corticosteroids, heparin, tetracyclines and nutrient solutions containing amino acids or fat emulsions.
Contraindications
Hypersensitivity. Positive aprotinin-specific IgG antibody test. Suspected previous exposure to aprotinin including fibrin sealant in the last 12 months.
Special Precautions
Renal impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity.
Cardiac disorders: Myocardial ischaemia, coronary occlusion/thrombosis, MI, pericardial effusion, atrial fibrillation.
Gastrointestinal disorders: Nausea, constipation, vomiting, diarrhoea.
General disorders and administration site conditions: Fever.
Renal and urinary disorders: Oliguria, acute renal failure, renal tubular necrosis.
Vascular disorders: Thrombosis, hypotension. Rarely, arterial thrombosis.
Potentially Fatal: Anaphylactic reactions.
MonitoringParameters
Monitor activated clotting time (ACT), fixed heparin dosing or heparin titration.
Drug Interactions
Dose-dependent inhibition on the effects of thrombolytic agents (e.g. streptokinase, urokinase, alteplase). Increased risk of renal dysfunction with aminoglycosides.
Lab Interference
Prolongs activated clotting time (ACT) in celite surface activation method in the presence of heparin.
Action
Description: Aprotinin, a haemostatic, acts as an inhibitor of proteolytic enzymes including chymotrypsin, kallikrein, plasmin, and trypsin. It also inhibits the contact phase activation of coagulation which both initiates coagulation and promotes fibrinolysis.
Pharmacokinetics:
Metabolism: Metabolised to shorter peptides or amino acids by lysosomal activity in the kidney.
Excretion: Via urine as inactive degradation products. Terminal elimination half-life: Approx 5-10 hours.
Storage
Store below 25°C. Protect from light. Do not freeze.
MIMS Class
ATC Classification
B02AB01 - aprotinin ; Belongs to the class of proteinase inhibitor antifibrinolytics. Used in the treatment of hemorrhage.
References
Aprotinin 10,000 KIU/mL Injection BP (Nordic Group b.v.). MHRA. https://products.mhra.gov.uk/. Accessed 01/07/2020.

Aprotinin. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 01/07/2020.

Buckingham R (ed). Aprotinin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/07/2020.

Trasylol (Bayer Pharmaceuticals Corporation). U.S. FDA. https://www.fda.gov/. Accessed 01/07/2020.

Disclaimer: This information is independently developed by MIMS based on Aprotinin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in